Literature DB >> 3510774

Milrinone and dobutamine in severe heart failure: differing hemodynamic effects and individual patient responsiveness.

W S Colucci, R F Wright, B E Jaski, M A Fifer, E Braunwald.   

Abstract

Milrinone and dobutamine were compared in 15 patients with New York Heart Association functional class III and IV congestive heart failure. Dobutamine and milrinone were administered intravenously according a graded titration schedule up to maximum doses (14 micrograms/kg/min and 75 micrograms/kg, respectively) or until increased ventricular ectopy or a reduction in left ventricular end-diastolic pressure to 10 mm Hg or less occurred. Although both agents markedly increased cardiac index, milrinone caused a significantly greater reduction in left and right heart filling pressures and mean arterial pressure than did dobutamine, and for any given increase in dP/dt, milrinone caused a greater reduction in systemic vascular resistance than did dobutamine. Thus, the hemodynamic effects of milrinone are best represented by a combination of the actions of dobutamine, a positive inotropic agent, and a vasodilator such as nitroprusside, which causes both arterial and venous dilation. The positive inotropic responses of individual patients to dobutamine (5 micrograms/kg/min) and milrinone (25 micrograms/kg) were compared. The increases in dP/dt with both agents were variable, and correlated poorly (r = .50; p = .059). Patients were divided into two groups: Group I consisted of eight patients in whom the ratio of the increase in dP/dt with dobutamine vs milrinone was greater than 1.0 (good dobutamine responders); group II consisted of seven patients in whom this ratio was less than 1.0 (poor dobutamine responders).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3510774

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  22 in total

1.  Use of a conductance catheter to detect increased left ventricular inotropic state by end-systolic pressure-volume analysis.

Authors:  G F Leatherman; T L Shook; S M Leatherman; W S Colucci
Journal:  Basic Res Cardiol       Date:  1989       Impact factor: 17.165

2.  Chronic inotropic therapy in end-stage heart failure.

Authors:  Paul J Hauptman; Peter Mikolajczak; Anil George; Clinton J Mohr; Robert Hoover; Jason Swindle; Mark A Schnitzler
Journal:  Am Heart J       Date:  2006-12       Impact factor: 4.749

3.  Acute Heart Failure Treatment.

Authors:  Phillip D Levy; Abdel Bellou
Journal:  Curr Emerg Hosp Med Rep       Date:  2013-06-01

4.  Levosimendan reverses right-heart failure in a 51-year-old patient after heart transplantation.

Authors:  Stjepan Barisin; Viktor Djuzel; Ana Barisin; Igor Rudez
Journal:  Wien Klin Wochenschr       Date:  2014-03-21       Impact factor: 1.704

Review 5.  [Cardiogenic shock].

Authors:  S Rasche; C Georgi
Journal:  Anaesthesist       Date:  2012-03       Impact factor: 1.041

Review 6.  Management of Cardiogenic Shock in a Cardiac Intensive Care Unit.

Authors:  Ju H Kim; Anusha Sunkara; Sara Varnado
Journal:  Methodist Debakey Cardiovasc J       Date:  2020 Jan-Mar

7.  Acute haemodynamic effects of different doses of alifedrine in congestive heart failure.

Authors:  I S Anand; L O Hughes; J R Whittington; E B Raftery
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

8.  [Cardiogenic shock].

Authors:  S Rasche; C Georgi
Journal:  Herz       Date:  2013-03       Impact factor: 1.443

Review 9.  Intravenous vasodilator therapy in congestive heart failure.

Authors:  Kourosh Moazemi; Jatinder S Chana; Anna Marie Willard; Abraham G Kocheril
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 10.  Phosphodiesterase inhibitors. Do the risks outweight the benefits?

Authors:  R Andrews; A J Cowley
Journal:  Drug Saf       Date:  1993-12       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.